AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilienceProactive Investors • 07/29/22
LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/27/22
AstraZeneca: Q2 2022 Earnings May Not Wow Investors - Steady Growth's The CharmSeeking Alpha • 07/25/22
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 07/25/22
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer StudyBenzinga • 07/19/22
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensBusiness Wire • 07/19/22
AstraZeneca acquires blood cancer specialist TeneoTwo for up to US$1.2bnProactive Investors • 07/05/22
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract CancersBusiness Wire • 07/01/22
Nuformix hoping to develop a 'bio-better' version of AstraZeneca blockbusterProactive Investors • 06/29/22